Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + finotonlimab
- Development stage
- Unknown
- Lead developer
- Sinocelltech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Docetaxel + finotonlimab is a combination therapy consisting of the chemotherapeutic agent docetaxel and the anti-programmed cell death protein 1 (PD-1) monoclonal antibody finotonlimab. Docetaxel is a taxane that stabilizes microtubules, thereby inhibiting cell division and inducing apoptosis in cancer cells. Finotonlimab (SCT-I10A) is an immune checkpoint inhibitor targeting PD-1, enhancing T-cell mediated antitumor responses. This combination has been investigated in phase II and III clinical trials for advanced squamous cell non-small cell lung cancer (sqNSCLC), where it demonstrated improved overall survival, progression-free survival, objective response rate, and disease control rate compared to docetaxel alone[1][2]. The regimen involves initial cycles of both drugs followed by maintenance monotherapy with finotonlimab.
- Other names
- finotonlimab + docetaxelSCT-I10A + docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on docetaxel + finotonlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + finotonlimab.